Which has preferable earnings and valuation, BIOA or TLX?

Telix Pharmaceuticals has higher revenue and earnings than BioAge Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $8.99M 110.36 -$80.61M -$2.40 N/A Telix Pharmaceuticals $803.79M 4.31 -$7.12M N/A N/A

Does the media favor BIOA or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than BioAge Labs. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for BioAge Labs. Telix Pharmaceuticals' average media sentiment score of 0.44 beat BioAge Labs' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BIOA or BEAM?

In the previous week, Beam Therapeutics had 6 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Beam Therapeutics and 1 mentions for BioAge Labs. Beam Therapeutics' average media sentiment score of 0.92 beat BioAge Labs' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BIOA or DYN?

In the previous week, Dyne Therapeutics had 13 more articles in the media than BioAge Labs. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for BioAge Labs. Dyne Therapeutics' average media sentiment score of 0.61 beat BioAge Labs' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIOA or ARQT?

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 1 mentions for BioAge Labs. Arcutis Biotherapeutics' average media sentiment score of 0.48 beat BioAge Labs' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ALMS or BIOA?

BioAge Labs has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $8.40M 371.91 -$243.32M -$1.98 N/A BioAge Labs $8.99M 110.36 -$80.61M -$2.40 N/A

Is ALMS or BIOA more profitable?

BioAge Labs has a net margin of -871.75% compared to Alumis' net margin of -2,825.70%. BioAge Labs' return on equity of -29.40% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% BioAge Labs -871.75% -29.40% -27.26%

BioAge Labs (BIOA) Competitors

$22.32 +0.85 (+3.96%)

Closing price 04:00 PM Eastern

Extended Trading

$22.33 +0.01 (+0.04%)

As of 06:56 PM Eastern

Compare

BIOA vs. TLX, BEAM, DYN, ARQT, and ALMS

Should you buy BioAge Labs stock or one of its competitors? MarketBeat compares BioAge Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAge Labs include Telix Pharmaceuticals (TLX), Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Arcutis Biotherapeutics (ARQT), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does BioAge Labs compare to Telix Pharmaceuticals?

BioAge Labs (NASDAQ:BIOA) and Telix Pharmaceuticals (NASDAQ:TLX) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Telix Pharmaceuticals has higher revenue and earnings than BioAge Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A
Telix Pharmaceuticals	$803.79M	4.31	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than BioAge Labs. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 1 mentions for BioAge Labs. Telix Pharmaceuticals' average media sentiment score of 0.44 beat BioAge Labs' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAge Labs presently has a consensus target price of $43.50, suggesting a potential upside of 94.89%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 106.90%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. Telix Pharmaceuticals' return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats BioAge Labs on 10 of the 12 factors compared between the two stocks.

How does BioAge Labs compare to Beam Therapeutics?

BioAge Labs (NASDAQ:BIOA) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Beam Therapeutics has higher revenue and earnings than BioAge Labs. Beam Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A
Beam Therapeutics	$139.74M	24.44	-$79.99M	-$0.68	N/A

Beam Therapeutics has a net margin of -39.66% compared to BioAge Labs' net margin of -871.75%. Beam Therapeutics' return on equity of -29.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

In the previous week, Beam Therapeutics had 6 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for Beam Therapeutics and 1 mentions for BioAge Labs. Beam Therapeutics' average media sentiment score of 0.92 beat BioAge Labs' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs currently has a consensus target price of $43.50, suggesting a potential upside of 94.89%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 41.06%. Given BioAge Labs' higher possible upside, equities research analysts clearly believe BioAge Labs is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

99.7% of Beam Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Beam Therapeutics beats BioAge Labs on 12 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Dyne Therapeutics?

BioAge Labs (NASDAQ:BIOA) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

BioAge Labs has higher revenue and earnings than Dyne Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

BioAge Labs presently has a consensus price target of $43.50, indicating a potential upside of 94.89%. Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 67.06%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dyne Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 13 more articles in the media than BioAge Labs. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for BioAge Labs. Dyne Therapeutics' average media sentiment score of 0.61 beat BioAge Labs' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dyne Therapeutics beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Arcutis Biotherapeutics?

BioAge Labs (NASDAQ:BIOA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of -0.57% compared to BioAge Labs' net margin of -871.75%. Arcutis Biotherapeutics' return on equity of -1.41% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than BioAge Labs. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 1 mentions for BioAge Labs. Arcutis Biotherapeutics' average media sentiment score of 0.48 beat BioAge Labs' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has higher revenue and earnings than BioAge Labs. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A
Arcutis Biotherapeutics	$376.07M	8.74	-$16.14M	-$0.03	N/A

BioAge Labs presently has a consensus target price of $43.50, suggesting a potential upside of 94.89%. Arcutis Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 29.43%. Given BioAge Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe BioAge Labs is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Arcutis Biotherapeutics beats BioAge Labs on 9 of the 14 factors compared between the two stocks.

How does BioAge Labs compare to Alumis?

Alumis (NASDAQ:ALMS) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Alumis currently has a consensus price target of $40.30, indicating a potential upside of 64.42%. BioAge Labs has a consensus price target of $43.50, indicating a potential upside of 94.89%. Given BioAge Labs' higher probable upside, analysts plainly believe BioAge Labs is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BioAge Labs has a net margin of -871.75% compared to Alumis' net margin of -2,825.70%. BioAge Labs' return on equity of -29.40% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
BioAge Labs	-871.75%	-29.40%	-27.26%

In the previous week, BioAge Labs had 1 more articles in the media than Alumis. MarketBeat recorded 1 mentions for BioAge Labs and 0 mentions for Alumis. Alumis' average media sentiment score of 0.00 equaled BioAge Labs'average media sentiment score.

Company	Overall Sentiment
Alumis	Neutral
BioAge Labs	Neutral

BioAge Labs has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	371.91	-$243.32M	-$1.98	N/A
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A

Alumis has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Summary

BioAge Labs beats Alumis on 9 of the 14 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$954.40M	$2.93B	$4.35B	$12.39B
Dividend Yield	N/A	15.20%	10.93%	5.83%
P/E Ratio	-9.30	13.43	22.00	23.97
Price / Sales	110.36	3,067.89	162.46	109.59
Price / Cash	N/A	26.91	40.77	54.51
Price / Book	2.94	4.85	18.62	6.50
Net Income	-$80.61M	-$34.85M	$115.37M	$336.88M
7 Day Performance	8.93%	-1.13%	-0.49%	-0.22%
1 Month Performance	34.38%	-0.85%	-1.84%	0.77%
1 Year Performance	N/A	15.04%	12.71%	31.57%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	2.4645 of 5 stars	$22.32 +4.0%	$43.50 +94.9%	N/A	$954.40M	$8.99M	N/A	N/A	News Coverage
TLX Telix Pharmaceuticals	4.1618 of 5 stars	$9.60 +0.4%	$21.13 +120.1%	-41.7%	$3.26B	$803.79M	N/A	1,184	News Coverage Positive News
BEAM Beam Therapeutics	3.2842 of 5 stars	$30.98 +6.7%	$46.83 +51.2%	+112.0%	$3.19B	$139.74M	N/A	510
DYN Dyne Therapeutics	2.6155 of 5 stars	$19.03 +4.6%	$35.00 +84.0%	+102.2%	$3.15B	N/A	N/A	100	Analyst Upgrade Gap Down
ARQT Arcutis Biotherapeutics	3.9482 of 5 stars	$25.08 +2.9%	$34.00 +35.5%	+92.9%	$3.14B	$376.07M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. TLX, BEAM, DYN, ARQT, and ALMS

How does BioAge Labs compare to Telix Pharmaceuticals?

Summary

How does BioAge Labs compare to Beam Therapeutics?

Summary

How does BioAge Labs compare to Dyne Therapeutics?

Summary

How does BioAge Labs compare to Arcutis Biotherapeutics?

Summary

How does BioAge Labs compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. TLX, BEAM, DYN, ARQT, and ALMS

How does BioAge Labs compare to Telix Pharmaceuticals?

Which has preferable earnings and valuation, BIOA or TLX?

Does the media favor BIOA or TLX?

Do analysts rate BIOA or TLX?

Which has more volatility and risk, BIOA or TLX?

Is BIOA or TLX more profitable?

Summary

How does BioAge Labs compare to Beam Therapeutics?

Which has stronger valuation & earnings, BIOA or BEAM?

Is BIOA or BEAM more profitable?

Which has more risk & volatility, BIOA or BEAM?

Does the media prefer BIOA or BEAM?

Do analysts rate BIOA or BEAM?

Do institutionals and insiders believe in BIOA or BEAM?

Summary

How does BioAge Labs compare to Dyne Therapeutics?

Which has preferable valuation and earnings, BIOA or DYN?

Which has more volatility and risk, BIOA or DYN?

Do analysts rate BIOA or DYN?

Do institutionals and insiders have more ownership in BIOA or DYN?

Is BIOA or DYN more profitable?

Does the media refer more to BIOA or DYN?

Summary

How does BioAge Labs compare to Arcutis Biotherapeutics?

Which has more volatility & risk, BIOA or ARQT?

Is BIOA or ARQT more profitable?

Does the media favor BIOA or ARQT?

Which has better valuation and earnings, BIOA or ARQT?

Do analysts recommend BIOA or ARQT?

Summary

How does BioAge Labs compare to Alumis?

Do analysts recommend ALMS or BIOA?

Is ALMS or BIOA more profitable?

Does the media prefer ALMS or BIOA?

Which has stronger valuation & earnings, ALMS or BIOA?

Which has more risk & volatility, ALMS or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools